Reports Q2 revenue $781,000 vs $0 last year. “Our four clinical-stage programs continue to make great progress, and we are excited to be advancing ulixacaltamide into Phase 3,” said Marcio Souza, president and chief executive officer of Praxis. “Our epilepsy portfolio continues to advance, with studies ongoing in each of our three clinical-stage programs that we expect to read out by the end of the year. We are planning to hold an R&D portfolio day on October 2 to elaborate on our science and clinical progress, including more details about the Phase 3 program for ulixacaltamide and additional data from the Essential1 study.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRAX:
- Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Praxis Precision Medicines announces data from Essential1 study
- Praxis Precision Medicines announces results of EEG analysis of PRAX-628 study
- Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
- Praxis Precision Medicines to Participate at the 2023 Wedbush PacGrow Healthcare Conference